A higher JAK2 V617F-mutated clone is observed in platelets than in granulocytes from essential thrombocythemia patients, but not in patients with polycythemia vera and primary myelofibrosis
- 15 March 2007
- journal article
- Published by Springer Nature in Leukemia
- Vol. 21 (6) , 1331-1332
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Molecular mimicry in the chronic myeloproliferative disorders: reciprocity between quantitative JAK2 V617F and Mpl expressionBlood, 2006
- The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia veraBlood, 2006
- JAK2 V617F in Myeloid Disorders: Molecular Diagnostic Techniques and Their Clinical UtilityThe Journal of Molecular Diagnostics, 2006
- JAK2 V617F mutation analysis in different myeloid lineages (granulocytes, platelets, CFU-MK, BFU-E and CFU-GM) in essential thrombocythemia patientsLeukemia, 2006
- JAK2V617F mutation in platelets from essential thrombocythemia patients: correlation with clinical features and analysis of STAT5 phosphorylation statusEuropean Journal of Haematology, 2006
- X-inactivation–based clonality analysis and quantitative JAK2V617F assessment reveal a strong association between clonality and JAK2V617F in PV but not ET/MMM, and identifies a subset of JAK2V617F-negative ET and MMM patients with clonal hematopoiesisBlood, 2006
- Essential thrombocythemias without V617F JAK2 mutation are clonal hematopoietic stem cell disordersLeukemia, 2006
- Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective studyThe Lancet, 2005
- Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disordersThe Lancet, 2005